Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M393Revenue (TTM) $M12.5Net Margin (%)-445.8Altman Z-Score-2.7
Enterprise Value $M344EPS (TTM) $-0.8Operating Margin %-399.6Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.8Pre-tax Margin (%)-431.1Higher ROA y-yN
Price/Book6.610-y EBITDA Growth Rate %--Quick Ratio7.9Cash flow > EarningsY
Price/Sales31.85-y EBITDA Growth Rate %--Current Ratio7.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %-494.3ROA % (ttm)-32.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-63.2Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M70.3ROIC % (ttm)-409.3Gross Margin Increase y-yN

Gurus Latest Trades with PGNX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

PGNX is held by these investors:



PGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Broadfin Healthcare Master Fun10% Owner 2017-02-15Sell602,600$9.66-42.13view
Broadfin Healthcare Master Fun10% Owner 2017-02-09Sell351,300$9.71-42.43view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-06-11Sell2,000$6.83-18.16view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-13Sell3,000$7-20.14view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-11Sell2,000$6.83-18.16view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-03Sell5,000$6.49-13.87view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-01-12Sell2,000$7.06-20.82view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-12-11Sell3,000$7.07-20.93view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-21Sell9,000$7-20.14view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-13Sell10,000$6.83-18.16view

Press Releases about PGNX :

Quarterly/Annual Reports about PGNX:

News about PGNX:

Articles On GuruFocus.com
Progenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Update Nov 02 2017 
Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA® (iobenguane I 131) in Pheochromoc Nov 02 2017 
Progenics Pharmaceuticals to Participate in November Investor Conferences Oct 31 2017 
Progenics Pharmaceuticals Sets Third Quarter 2017 Financial Results Call for November 2 Oct 23 2017 
Progenics Pharmaceuticals Announces Presentations on AZEDRA® (iobenguane I 131) and its Prostate Oct 16 2017 
Data from Pivotal Phase 2b Study of Progenics’ AZEDRA® (iobenguane I 131) to be Presented at Oct 04 2017 
Progenics Pharmaceuticals to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference Sep 20 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenics Pharma Sep 01 2017 
Progenics Pharmaceuticals Presents Data from AZEDRA® Pivotal Phase 2b Study at the 5th Internatio Aug 31 2017 
Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA® Aug 31 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK